Form 8-K - Current report:
SEC Accession No. 0001213900-25-001211
Filing Date
2025-01-06
Accepted
2025-01-06 17:00:09
Documents
14
Period of Report
2025-01-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0226487-8k_abvcbio.htm   iXBRL 8-K 28204
2 LETTER AGREEMENT ea022648701ex10-1_abvcbio.htm EX-10.1 29749
  Complete submission text file 0001213900-25-001211.txt   240622

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE abvc-20250106.xsd EX-101.SCH 3021
4 XBRL LABEL FILE abvc-20250106_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE abvc-20250106_pre.xml EX-101.PRE 22363
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0226487-8k_abvcbio_htm.xml XML 3568
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

IRS No.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40700 | Film No.: 25512100
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)